Decoupling weight loss from organoprotective benefits in GLP-1RA, dual agonists, and SGLT2I therapy: A narrative review

Over the past decade, incretin-based therapies and SGLT2 inhibitors have redefined management of type 2 diabetes (T2D) and obesity. While their glucose-lowering and weight-reducing properties are well established, growing evidence highlights benefits that extend beyond these metabolic endpoints. Large cardiovascular outcome trials, renal protection programs, and liver disease studies demonstrate that reductions in cardiovascular events, kidney failure, and steatohepatitis are only partly explained by changes in body weight or glycated hemoglobin. Instead, these agents may exert direct disease-modifying actions through anti-inflammatory, antifibrotic, hemodynamic, and endothelial pathways. This narrative review synthesizes evidence from major randomized trials and large prospective cohorts published between 2010 and 2025, prioritized based on hard clinical endpoints and relevance to organ-protection outcomes. Trials such as SURPASS-CVOT, SOUL, SELECT, SUSTAIN-6, LEADER, REWIND, EMPA-REG OUTCOME, DAPA-CKD, EMPA-KIDNEY, and ESSENCE collectively illustrate protection across cardiovascular, renal, and hepatic systems. Importantly, trials conducted predominantly in individuals with higher baseline body weight demonstrated more pronounced weight loss, whereas other pivotal trials involving participants with lower baseline weight showed comparable organoprotective benefits despite far smaller weight changes—highlighting that these effects extend beyond the advantages conferred by weight reduction alone. Emerging data also suggest possible benefits in neurological and respiratory domains. Recognition of these broader effects has important implications for chronic disease management and the development of future therapeutic paradigms.